We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to ...
Fintel reports that on February 7, 2025, Citigroup initiated coverage of Cytokinetics (NasdaqGS:CYTK) with a Buy ...
Cytokinetics (CYTK) was initiated by Citi analysts with a Buy rating, citing potential FDA approval for its lead asset ...
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is ...
Citi initiated coverage of Cytokinetics (CYTK) with a Buy rating and $86 price target. The shares seem attractive at current levels, given the ...
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cytokinetics (CYTK – Research Report) and ...
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the ...
Cytokinetics' flagship program, aficamten, is a cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy (HCM), a condition characterized by thickening of the heart muscle.
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on January 31, 2025 it granted stock options to purchase an aggregate ...
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to ...
Inspire Investing LLC boosted its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 7.8% in the ...